Upcoming FDA Decision on June 29th on approval of a small cap company's drug for Anemia patients

The upcoming FDA Decision date on JUNE 29th (Monday) for AMAG's Feraheme for iron deficiency in Anemia patients is a critical event for the company. If the FDA approves this drug, it could become the gold standard for iron deficiency in anemic patients who have chronic kidney disease. To read about our opinion on whether Feraheme will be approved or not, along with details of the company, the drug, the disease, the competitors, the market and the sales potential of the drug (if approved), get a FREE report at: http://www.newbiomedicine.com